Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of anlotinib in combination with nivilumab as
second-line treatment in advanced NSCLC patients. The primary endpoint of the study is
progression-free survival (PFS);the secondary endpoints are disease control rate (DCR),
objective response rate (ORR), overall survival (OS) and safety.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University